The Effect of Theobromine on Blood Lipid Parameters in Healthy Subjects

NCT ID: NCT01481389

Last Updated: 2012-09-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

152 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the effect of theobromine on blood lipid parameters in healthy subjects. Secondary objectives are to determine the effect of cocoa and an interaction effect of cocoa and theobromine on blood lipid parameters.

Hypothesis: theobromine has a positive effect on blood lipid parameters.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Diseases

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Blood lipids risk factor for cardiovascular diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Theobromine drink

Group Type ACTIVE_COMPARATOR

Theobromine

Intervention Type DIETARY_SUPPLEMENT

200 ml drink with added theobromine (no cocoa added)

Cocoa drink

Group Type ACTIVE_COMPARATOR

Cocoa

Intervention Type DIETARY_SUPPLEMENT

200 ml drink with cocoa (no theobromine added)

Placebo drink

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

200 ml drink (no added theobromine or cocoa)

Cocoa and theobromine drink

Group Type ACTIVE_COMPARATOR

Cocoa and theobromine

Intervention Type DIETARY_SUPPLEMENT

200 ml drink with added cocoa and theobromine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Theobromine

200 ml drink with added theobromine (no cocoa added)

Intervention Type DIETARY_SUPPLEMENT

Cocoa

200 ml drink with cocoa (no theobromine added)

Intervention Type DIETARY_SUPPLEMENT

Cocoa and theobromine

200 ml drink with added cocoa and theobromine

Intervention Type DIETARY_SUPPLEMENT

Placebo

200 ml drink (no added theobromine or cocoa)

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Apparently healthy men and post-menopausal women: no medical conditions which might affect study measurements (judged by study physician)
* Willing and able to participate in the study protocol
* Written informed consent
* Age 40-70 years
* 10-year risk of developing CHD \<10%, based on data from the Framingham Heart Study
* BMI \> 18 and \< 30 kg/m2
* Blood pressure, heart rate, haematological and clinical chemical parameters within the normal reference range as judged by research physician
* Willing to comply with the dietary restrictions of the study.
* Accessible veins on arm(s) as determined by examination at screening

Exclusion Criteria

* Previous cardiovascular event(s) (stroke, TIA, angina, myocardial infarction, heart failure)
* Diabetes mellitus
* Reported alcohol consumption \> 14 units/week (female) or \> 21 units/week (male)
* Currently on a medically prescribed diet, or slimming diet
* Reported weight loss or gain of 10% body weight or more during a period of 6 months before pre-study examination
* Reported intense sporting activities \> 10 h/w
* Use of prescribed medication which may interfere with study measurements, as judged by the physician
* Use of antibiotics in the three months before screening or during the study.
* Currently smoking or being a non-smoker for less than 6 months and reported use of any nicotine containing products in the 6 months preceding the study and during the study itself
* Reported intolerance to test products or other food products provided during the study
* Blood donation 1 month (males) or 2 months (females) prior to screening and during the study
* Reported participation in another nutritional or biomedical trial 3 months before screening or during the study.
* Extreme coffee consumption
Minimum Eligible Age

40 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Unilever R&D

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Wieneke Koppenol, MSc

Role: STUDY_DIRECTOR

Unilever R&D

Nicole Neufingerl, MSc

Role: STUDY_DIRECTOR

Unilever R&D

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Eurofins Optimed

Gières, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Neufingerl N, Zebregs YE, Schuring EA, Trautwein EA. Effect of cocoa and theobromine consumption on serum HDL-cholesterol concentrations: a randomized controlled trial. Am J Clin Nutr. 2013 Jun;97(6):1201-9. doi: 10.3945/ajcn.112.047373. Epub 2013 Apr 17.

Reference Type DERIVED
PMID: 23595874 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

10022V

Identifier Type: -

Identifier Source: org_study_id